Loading…
← CockpitCompetitor Analysis › 002004.SZ Huapont Life Sciences Co., Ltd. Class AOpen in the cockpit ↗

Huapont Life Sciences Co., Ltd. Class A002004.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Agricultural

Chinese company spanning pharmaceuticals and agrochemical/chemical manufacturing, having pivoted from its original pesticide business into life sciences.

Momentum leader 90
Mkt cap
$1.33B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$18.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+1.5 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Close · CNYCN¥4.54
1D-0.7%
1W-0.2%
1M+5.3%
3M0.0%
6M-4.8%
YTD-5.0%
1Y-7.2%
ATR %2.5%
52w lowhigh25.3% off high

What Huapont Life Sciences does

Chinese company spanning pharmaceuticals and agrochemical/chemical manufacturing, having pivoted from its original pesticide business into life sciences.

Products and services

  • Pharmaceutical products
  • Legacy agrochemical business

Customers

  • Hospitals/pharmacies
  • Agrochemical distributors

Where it sits in the supply chain

  • Health Care
  • Diversified chemicals & pharmaceuticals

What could go wrong

  • Diversified/unfocused business mix

Moat: none. Diversified holding spanning pharma and chemicals without a clear single-business moat.

Headquarters: Wuhan, China · Employees: 11,950

Huapont Life Sciences at a glance

Size Huapont Life Sciences (002004.SZ) is a China Materials company (Chemicals: Agricultural) with a market value of $1.33B, the 1694th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.54 on 18 Nov 2026.

Performance Over six months the shares fell 4.8%, against -22.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 5.6% over the last twelve months (peer median +7.2%); the operating margin is 11.3% (peer median 7.2%).

Valuation It trades at 1.7× enterprise value to sales against a peer median of 1.6× (10th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.5 points above its cost of capital (5.0% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026002004.SZ 96Peer median 78
Six months, rebased to 100: Huapont Life Sciences against the median of its 20 peers (local-currency closes).

Huapont Life Sciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥11.1BCN¥11.5BCN¥11.6BCN¥11.5BCN¥13.2B
Revenue growth—-1%+1%-12%—
Gross profitCN¥4.91BCN¥3.92BCN¥3.66BCN¥4.19BCN¥5.06B
EBITDAn/aCN¥2.51BCN¥2.09BCN¥2.26BCN¥2.71B
Net incomeCN¥572MCN¥713M-CN¥299MCN¥302MCN¥433M
Free cash flowCN¥2.09BCN¥1.60BCN¥872MCN¥436MCN¥1.50B
Capital expenditureCN¥541MCN¥638MCN¥956MCN¥1.28BCN¥1.13B
Total debtCN¥7.79BCN¥8.14BCN¥9.74BCN¥9.81BCN¥9.20B

Quarterly statements and history in the cockpit →

Huapont Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%0025881866002217002170EIDPARRY603299000422PARADEEPATUL1722600596BAYERCROP9879002258301665002215TATACHEM0297UAN3983002004.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Huapont Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×2×4×0025881866002217002170EIDPARRY603299000422PARADEEPATUL1722BAYERCROP9879002258301665002215TATACHEM0297UAN002004.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Huapont Life Sciences is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%+40%-25%0%25%002217002170ATUL172260059698793016650022150297UAN002004.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Huapont Life Sciences is the large dot.

Huapont Life Sciences competitors and peer comparison

How Huapont Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Huapont Life Sciences against its 20 peers (data as of 18 Nov 2026)
Measure002004.SZPeer medianRank in peer set
1-month return+5.3%-7.2%highest of 21
6-month return-4.8%-22.6%4th highest of 21
Distance from 52-week high-25.3%-34.3%4th highest of 21
Revenue growth (TTM)-5.6%+7.2%lowest of 21
Operating margin11.3%7.2%7th highest of 21
EV / Sales1.7×1.6×10th most expensive of 20
Growth the price implies (Req g, 7 yrs)-8.9%-2.3%3rd least demanding of 12
Growth delivered (Del g)+1.1%+6.9%3rd lowest of 12
Hurdle (Req g minus delivered)-10.1 pp-13.2 pp6th most demanding of 12
ROIC minus cost of capital+1.5 pp+0.2 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Huapont Life Sciences 002004.SZChina$1.33B-5%-6%11%1.7×-8.9%+1.1%
Stanley Agricultural 002588.SZChina$1.33B-23%+3%8%0.8×n/an/a
China XLX Fertiliser 1866.HKHong Kong$1.41B-21%+24%8%1.1×n/an/a
Holitech Technology 002217.SZChina$1.26B-65%+17%2%4.6×43.3%-37.1%
Shenzhen Batian Ecological Technique 002170.SZChina$1.42B-22%+3%23%2.1×-8.1%+18.8%
E.I.D.-Parry (India) EIDPARRY.NSIndia$1.23B-18%+7%6%0.5×n/an/a
Jiang Su Suyan Jingshen 603299.SSChina$1.22B-19%-5%5%1.9×n/an/a
Hubei Yihua Chemical Industry 000422.SZChina$1.48B-40%+15%5%1.5×n/an/a
Paradeep Phosphates PARADEEP.NSIndia$1.54B+12%+31%7%1.0×n/an/a
Atul ATUL.NSIndia$1.58B-29%+18%12%1.9×17.5%+11.0%
Taiwan Fertilizer 1722.TWTaiwan$1.12B-17%+4%4%3.0×26.2%+3.5%
Zhejiang Xinan Chemical Industrial 600596.SSChina$1.59B-33%+5%2%0.9×10.9%+3.1%
Bayer Cropscience India BAYERCROP.NSIndia$1.61B-23%-5%15%2.8×16.5%+5.9%
Migao 9879.HKHong Kong$1.07B+5%+27%8%1.2×-2.3%+23.4%
Lier Chemical 002258.SZChina$1.67B+14%+6%8%1.8×n/an/a
CAC Nantong Chemical 301665.SZChina$1.06B-29%+27%13%1.4×-3.0%+11.9%
Shenzhen Noposion Crop Science 002215.SZChina$1.03B-32%+12%13%1.9×-6.2%+6.9%
Tata Chemicals TATACHEM.NSIndia$1.73B-14%+5%2%1.6×n/an/a
Sinofert 0297.HKHong Kong$1.01B-23%+16%6%0.2×-19.1%+1.0%
CVR Partners, LP UANUnited States$1.01B-22%+7%21%2.2×-11.7%+11.6%
China BlueChemical 3983.HKHong Kong$999M-30%+4%5%n/an/an/a

Questions

Which companies are Huapont Life Sciences's closest peers?
The cockpit's peer set: Stanley Agricultural (002588.SZ), China XLX Fertiliser (1866.HK), Holitech Technology (002217.SZ), Shenzhen Batian Ecological Technique (002170.SZ), E.I.D.-Parry (India) (EIDPARRY.NS), Jiang Su Suyan Jingshen (603299.SS), Hubei Yihua Chemical Industry (000422.SZ), Paradeep Phosphates (PARADEEP.NS).
Is Huapont Life Sciences expensive compared with its peers?
On ev / sales it trades at 1.7× against a peer median of 1.6×, 10th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Huapont Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned -4.8% against -22.6% for the median peer; over one year -7.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.